Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · IEX Real-Time Price · USD
21.55
+1.63 (8.18%)
Jun 2, 2023, 4:00 PM EDT - Market closed
Enliven Therapeutics Market Cap
Enliven Therapeutics has a market cap or net worth of $886.02 million as of June 2, 2023. Its market cap has increased by 2,617.86% in one year.
Market Cap
886.02M
Enterprise Value
593.87M
1-Year Change
2,617.86%
Ranking
Category
Stock Price
$21.55
Market Cap Chart
Since March 12, 2020, Enliven Therapeutics's market cap has increased from $244.90M to $886.02M, an increase of 261.79%. That is a compound annual growth rate of 49.05%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 1, 2023 | 819.00M | 8.85% |
| May 31, 2023 | 752.40M | 1.16% |
| May 30, 2023 | 743.80M | -7.80% |
| May 26, 2023 | 806.70M | -0.20% |
| May 25, 2023 | 808.30M | -0.31% |
| May 24, 2023 | 810.80M | 0.46% |
| May 23, 2023 | 807.10M | -8.40% |
| May 22, 2023 | 881.10M | 6.14% |
| May 19, 2023 | 830.10M | 0.64% |
| May 18, 2023 | 824.80M | 0.30% |
| May 17, 2023 | 822.30M | 0.91% |
| May 16, 2023 | 814.90M | -0.05% |
| May 15, 2023 | 815.30M | 2.22% |
| May 12, 2023 | 797.60M | 1.57% |
| May 11, 2023 | 785.30M | 502.69% |
| May 10, 2023 | 130.30M | 3.49% |
| May 9, 2023 | 125.90M | 0.32% |
| May 8, 2023 | 125.50M | -2.56% |
| May 5, 2023 | 128.80M | 5.14% |
| May 4, 2023 | 122.50M | -5.41% |
| May 3, 2023 | 129.50M | 3.43% |
| May 2, 2023 | 125.20M | -1.11% |
| May 1, 2023 | 126.60M | 1.36% |
| Apr 28, 2023 | 124.90M | 0.48% |
| Apr 27, 2023 | 124.30M | -2.81% |
View and export this data all the way back to 2020.
Start Free Trial.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| MoonLake Immunotherapeutics | 1.22B |
| Structure Therapeutics Inc. | 1.21B |
| Replimune Group, Inc. | 1.07B |
| Inhibrx, Inc. | 1.03B |
| Cullinan Oncology, Inc. | 398.33M |
| Aerovate Therapeutics, Inc. | 394.79M |
| Compass Therapeutics, Inc. | 355.48M |
| Theseus Pharmaceuticals, Inc. | 318.54M |
| Nuvectis Pharma, Inc. | 275.49M |
| PMV Pharmaceuticals, Inc. | 243.07M |
| Celcuity Inc. | 232.98M |
| Immuneering Corporation | 202.69M |
| Merrimack Pharmaceuticals, Inc. | 178.54M |
| Gossamer Bio, Inc. | 120.26M |
| Kronos Bio, Inc. | 89.33M |
| Lyra Therapeutics, Inc. | 82.14M |
| Eliem Therapeutics, Inc. | 82.06M |